Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM

NCT03072407 is registered in ClinicalTrials.gov with PegBio Co., Ltd. as lead sponsor.

NCT NCT03072407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03072407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM
Lead sponsor
PegBio Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 24, 2015
Completion date
November 15, 2016
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

type2 diabetes mellitus